Search results for "Psychotic"

showing 10 items of 360 documents

Dopamine agonists in schizophrenia: a review.

1995

Although it is unlikely that the different types of course and severity of schizophrenia are caused by one neurochemical abnormality alone, indirect pharmacological evidence still suggests a relative excess of dopaminergic activity being implicated in the pathogenesis of most of the schizophrenic symptoms, e.g. positive symptomatology. Synthesis and release of dopamine as well as firing rates of dopaminergic neurons are controlled by stimulation of autoreceptors via a negative feedback regulation. Investigations on therapeutic effects of autoreceptor-nonselective dopamine agonists in schizophrenia have yielded inconsistent results. Dopamine autoreceptor agonists like pramipexole, roxindole,…

medicine.medical_specialtychemistry.chemical_compoundNeurochemicalPramipexoleRoxindoleDopamine receptor D3DopamineInternal medicineDopamine receptor D2medicineHumansPharmacology (medical)BenzothiazolesBiological PsychiatryAutoreceptorsPharmacologyPramipexoleDopaminergicAzepinesTalipexolePsychiatry and Mental healthThiazolesEndocrinologyNeurologychemistryDopamine AgonistsSchizophreniaNeurology (clinical)Psychologymedicine.drugAntipsychotic AgentsEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
researchProduct

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders.

2007

These practical guidelines for the biological treatment of personality disorders in primary care settings were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). They embody the results of a systematic review of all available clinical and scientific evidence pertaining to the biological treatment of three specific personality disorders, namely borderline, schizotypal and anxious/avoidant personality disorder in addition to some general recommendations for the whole field. The guidelines cover disease definition, classification, epidemiology, course and current knowledge on biological underpinnings, and provide a detailed overview …

medicine.medical_specialtymedia_common.quotation_subjectSadistic personality disorderAvoidant personality disorderPersonality DisordersSchizotypal Personality DisorderBorderline Personality DisordermedicinePersonalityHumansPsychiatryBorderline personality disorderBiological PsychiatrySocieties Medicalmedia_commonPsychiatryEvidence-Based Medicinemedicine.diseaseSchizotypal personality disorderPersonality disordersAntidepressive AgentsPsychotherapyPsychiatry and Mental healthBiological psychiatryPsychologyPsychopathologyClinical psychologyAntipsychotic AgentsThe world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
researchProduct

Pharmacotherapy of Borderline Personality Disorder: A Metaanalysis of Randomised Controlled Trials

2009

Background:In Borderline Personality Disorder (BPD), pharmacotherapy is used for the treatment of specific BPD pathology facets, such as cognitive-perceptual, affective, or impulsivity symptoms. Due to the polymorphic phenomenology of the disorder, different classes of drugs are used, e.g., antipsychotics, antidepressants, or mood stabilizers.Aims:To evaluate the up-to-date evidence of drug treatment efficacy for BPD.Method:A systematic review and metaanalysis of randomised controlled trials was done. All randomised comparisons of drug vs. placebo, drug vs. drug, or drug vs. a combination of drugs in adult BPD patients were eligible for inclusion. Outcomes comprised BPD core pathology as de…

medicine.medical_specialtymedicine.medical_treatmentImpulsivitymedicine.diseasePsychiatry and Mental healthMoodTolerabilitymedicineAnxietymedicine.symptomAdverse effectPsychiatryAntipsychoticPsychologyBorderline personality disorderPsychopathologyClinical psychologyEuropean Psychiatry
researchProduct

Clozapine-related drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review.

2020

The Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome is a severe, multiorganic, and potentially life-threatening drug-induced hypersensitivity reaction, linked to several common drugs, including antiepileptics, antibiotics, and several psychotropic drugs, including clozapine. Due to the importance of clozapine in the management of treatment-resistant schizophrenia, a systematic review and characterization of clozapine-related DRESS syndrome is long overdue.This systematic review was conducted following PRISMA guidelines. PubMed, Embase, PsychINFO, and the Cochrane Library databases were independently reviewed up to 1 November 2019 for articles reporting clozapine-relat…

medicine.medical_specialtymedicine.medical_treatmentmacromolecular substances030226 pharmacology & pharmacyDrug reaction with eosinophilia and systemic symptoms03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesMedicineHumansPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsAntipsychoticClozapineClozapinebusiness.industrymusculoskeletal neural and ocular physiologyGeneral Medicinemedicine.diseaseDermatologyHypersensitivity reactionnervous system030220 oncology & carcinogenesisDrug Hypersensitivity SyndromePolypharmacySchizophreniabusinessmedicine.drugAntipsychotic AgentsExpert review of clinical pharmacology
researchProduct

Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics

2021

Over the last two decades, pharmacogenetics and pharmacokinetics have been increasingly used in clinical practice in Psychiatry due to the high variability regarding response and side effects of antipsychotic drugs. Specifically, long-acting injectable (LAI) antipsychotics have different pharmacokinetic profile than oral formulations due to their sustained release characteristics. In addition, most of these drugs are metabolized by CYP2D6, whose interindividual genetic variability results in different metabolizer status and, consequently, into different plasma concentrations of the drugs. In this context, there is consistent evidence which supports the use of therapeutic drug monitoring (TD…

medicine.medical_treatmentPopulationAripiprazolePharmaceutical ScienceContext (language use)ReviewPharmacology030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicinearipiprazolePharmacy and materia medicamedicineAntipsychoticsPaliperidoneeducationAntipsychoticPopulation pharmacokinetic modelspharmacogeneticseducation.field_of_studyRisperidonerisperidonemedicine.diagnostic_testbusiness.industryCYP2D6PaliperidoneRisperidoneLAIRS1-441antipsychoticsTherapeutic drug monitoringpopulation pharmacokinetic modelsPharmacogeneticsAripiprazolebusinesspaliperidone030217 neurology & neurosurgeryPharmacogeneticsmedicine.drug
researchProduct

What we learn about bipolar disorder from large-scale neuroimaging

2020

Abstract MRI‐derived brain measures offer a link between genes, the environment and behavior and have been widely studied in bipolar disorder (BD). However, many neuroimaging studies of BD have been underpowered, leading to varied results and uncertainty regarding effects. The Enhancing Neuro Imaging Genetics through Meta‐Analysis (ENIGMA) Bipolar Disorder Working Group was formed in 2012 to empower discoveries, generate consensus findings and inform future hypothesis‐driven studies of BD. Through this effort, over 150 researchers from 20 countries and 55 institutions pool data and resources to produce the largest neuroimaging studies of BD ever conducted. The ENIGMA Bipolar Disorder Workin…

mega-analysisStress-related disorders Donders Center for Medical Neuroscience [Radboudumc 13]cortical surface areaReview Article0302 clinical medicineManic-depressive illnessMulticenter Studies as TopicSpectrum disorderReview Articlesbipolar disorderCerebral CortexTrastorn bipolarneuroimagingRadiological and Ultrasound Technology05 social sciencesENIGMAHUMAN BRAINMagnetic Resonance Imagingpsychiatry3. Good healthNeurologyMeta-analysisScale (social sciences)AnatomyPsychologyClinical risk factorClinical psychologyMRIMAJOR PSYCHIATRIC-DISORDERSSchizoaffective disorder050105 experimental psychology03 medical and health sciencesMagnetic resonance imagingNeuroimagingMeta-Analysis as TopicSDG 3 - Good Health and Well-beingImatges per ressonància magnèticamedicineHumans0501 psychology and cognitive sciencesRadiology Nuclear Medicine and imagingBipolar disorderHIPPOCAMPAL VOLUMESmega‐analysisGRAY-MATTER VOLUMESPECTRUM DISORDERvolumeDIABETES-MELLITUScortical thicknessCOGNITIVE IMPAIRMENTmedicine.diseaseMental illnessmeta-analysismeta‐analysisRC0321Neurology (clinical)SCHIZOAFFECTIVE DISORDERPSYCHOTIC FEATURES030217 neurology & neurosurgeryHuman Brain Mapping
researchProduct

Personality Profile in Orthorexia Nervosa and Healthy Orthorexia

2021

Little is known about orthorexia in both its pathological (orthorexia nervosa, OrNe) and adaptive (healthy orthorexia, HeOr) forms. To date, few studies have been carried out to analyze the personality profile associated with orthorexia, and the results have been contradictory. The aim of the present study was to explore the characteristic pathological personality traits associated with OrNe and HeOr. A total of 297 participants (Mage= 30.8 years; 94.6% women) from the general population completed the Teruel Orthorexia Scale (TOS) and Personality Inventory for DSM-5-Short Form (PID-5-SF) questionnaires. Results showed significant low-medium correlations between OrNe and the four personality…

personality profilemedia_common.quotation_subjectPopulationDisinhibitionNegative affectivityhealthy orthorexiaPsychoticismmental disordersmedicinePsychologyneuroticismeducationGeneral PsychologyOrthorexia nervosamedia_commoneducation.field_of_studyBrief Research Reportmedicine.diseaseNeuroticismBF1-990orthorexia nervosaFeelingDisinhibitionpsychoticismmedicine.symptomPersonality Assessment InventoryPsychologyClinical psychologyFrontiers in Psychology
researchProduct

SCHIZOFRENIA E ADATTAMENTO NEL CASO DI BEATRICE

2017

This paper is focused on the outcomes of psychotic functioning and, in particular, on individual and contextual elements that could influence the level of adjustment of a patient with schizophrenia. The case of Beatrice, who was diagnosed with schizophrenia at the age of 23, is analyzed using the personal diary that she herself compiled over about fifty years, in which she documented the fundamental events of her life. In the story of B. certain protective factors were highlighted, which enabled B. to have a good quality of life: effective pharmacological therapy with no side-effects, awareness of the pathology, the capacity to build satisfying interpersonal relationships and her religious …

psychotic disorders schizophrenia family relations risk factors protective factors.Settore M-PSI/07 - Psicologia Dinamica
researchProduct

Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with …

2019

ObjectiveOur aim was to summarize the efficacy and safety of atomoxetine, amphetamines, and methylphenidate in schizophrenia.MethodsWe undertook a systematic review, searching PubMed/Scopus/Clinicaltrials.gov for double-blind, randomized, placebo-controlled studies of psychostimulants or atomoxetine in schizophrenia published up to 1 January 2017. A meta-analysis of outcomes reported in two or more studies is presented.ResultsWe included 22 studies investigating therapeutic effects of stimulants (k=14) or measuring symptomatic worsening/relapse prediction after stimulant challenge (k=6). Six studies of these two groups plus one additional study investigated biological effects of psychostimu…

safetymedicine.medical_specialtyPsychosismedicine.medical_treatmentefficacyamphetamineSchizoaffective disorderAtomoxetine Hydrochloridemeta-analysi03 medical and health sciencesExecutive Function0302 clinical medicinesystematic reviewInternal medicinemedicineHumansAttentionAmphetamineProblem Solvingbusiness.industryMethylphenidateAtomoxetineAmphetaminesrelapse predictorstimulantmedicine.disease030227 psychiatryStimulantPsychiatry and Mental healthMemory Short-Termamphetamine atomoxetine efficacy meta-analysis methylphenidate relapse predictor safety schizophrenia stimulants systematicn reviewPsychotic DisordersSchizophreniaMeta-analysisMethylphenidateSchizophreniaNeurology (clinical)businessatomoxetine030217 neurology & neurosurgerymedicine.drugAntipsychotic Agents
researchProduct

Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia

2017

ObjectiveOur aim was to perform an updated systematic review and meta-analysis on the efficacy and safety of adjunctive minocycline as a treatment of schizophrenia.MethodsWe conducted a PubMed/Scopus database search from inception to 3 February 2016 for randomized, placebo-controlled trials (RCTs), open non-randomized studies, and case reports/series evaluating minocycline in patients with schizophrenia. Random-effects meta-analysis of positive, negative, depressive, and cognitive symptom rating scales, discontinuation and adverse effects rates calculating standardized mean difference (SMD), and risk ratios±95% confidence intervals (CI95%) were calculated.ResultsSix RCTs were eligible (mino…

safetymedicine.medical_specialtyefficacyMinocyclinePlacebometa-analysi03 medical and health sciences0302 clinical medicinesystematic reviewInternal medicineefficacy; meta-analysis; Minocycline; safety; schizophrenia; systematic review; Neurology (clinical); Psychiatry and Mental HealthMedicineHumansRandomized Controlled Trials as TopicPositive and Negative Syndrome Scalebusiness.industryMinocycline schizophrenia efficacy safety meta-analysis systematic reviewConfidence interval030227 psychiatryDiscontinuationAnti-Bacterial Agentsmeta-analysisschizophreniaTolerabilityStrictly standardized mean differencePsychiatry and Mental HealthMeta-analysisAdjunctive treatmentNeurology (clinical)business030217 neurology & neurosurgeryAntipsychotic Agents
researchProduct